- Company
- Yuhan earns ₩80B milestone with Leclaza's FDA nod
- by Chon, Seung-Hyun Sep 12, 2024 05:51am
- On the 11th, Yuhan Corp announced that it will receive USD 60 million (approximately KRW 80 billion) as milestone payments from Janssen Biotech for Leclaza. The company explained, “This is a milestone payment (step-by-step technical fee) for the commercialization of Leclaza and Janssen Biotech's amivantamab combination therapy.” The
- Company
- HK inno.N signs supply deal with Pfizer for COVID-19 vaccine
- by Son, Hyung-Min Sep 12, 2024 05:51am
- HK inno.N announced on September 11th that it has signed an agreement with Pfizer Korea for the domestic distribution of the new COVID-19 vaccine. On September 10th, two companies held an agreement ceremony celebrating the strategic collaboration for the distribution of Pfizer Korea's COVID-19 vaccine, 'Comirnaty JN.1 Inj (bretovameran),
- Company
- Celltrion aims for KRW 5T sales with 'ADC‧CDMO'
- by Hwang, Byung-woo Sep 12, 2024 05:51am
- Celltrion aims to achieve KRW 5 trillion in sales by 2025 based on the growth of the biosimilar pipeline and new business operations. Celltrip Group President Seo Jung-jin and Celltrion CEO Seo Jin-seok announced on September 9th that they have participated in the 'Morgan Stanley 22nd Annual Global Healthcare Conference' in the United St
- Company
- Switching between JAKis reimbursed for rheumatoid arthritis
- by Eo, Yun-Ho Sep 12, 2024 05:50am
- The issue of reimbursement being not allowed for switching between JAK inhibitors in rheumatoid arthritis, which has been a pet peeve on site, will be resolved soon. According to Dailypharm coverage, the health authorities decided to allow insurance reimbursement benefits for cross-dosing between JAK inhibitors in rheumatoid arthritis in
- Company
- LG Chem appeals... starts 2nd patent trial for Zemiglo
- by Kim, Jin-Gu Sep 12, 2024 05:50am
- The patent dispute over the use of DPP-4 inhibitor class diabetes drug Zemiglo (gemigliptin) is heading on to its second round. Generic companies have succeeded in winning both the evasion and invalidation trials regarding Zemiglo's use patent, after which LG Chem has appealed to the Intellectual Property High Court of Korea. According
- Company
- Which company will distribute Bayer's 'Canesten·Bepanthen'?
- by Nho, Byung Chul Sep 12, 2024 05:50am
- As the co-promotion agreement between Bayer and Il Dong Pharmaceutical for over the counter (OTC) medicines is set to expire, it gathers attention whether the company will renew the contract. According to industry sources, Bayer is searching for a new distributor to distribute its OTC medicines, Canesten and Bepanthen. Il Dong Pharmaceu
- Company
- GSK seeks mutual growth with its employees…top satisfaction
- by Hwang, Byung-woo Sep 11, 2024 04:39pm
- ‘Vaccine powerhouse’ is the first image that comes to mind upon the mention of GSK these days. The company has been constantly exerting its influence with its range of vaccines for various vaccine-preventable diseases. In the specialty medicine space, the company has expanded its pipeline to include respiratory asthma and COPD, as wel
- Company
- Pharma's China subsidiaries undergo massive changes
- by Kim, Jin-Gu Sep 11, 2024 05:54am
- China subsidiaries of South Korea's listed pharmaceutical and biotech companies are undergoing massive changes. Il-Yang Pharmaceutical and GC Biopharma have liquidated or sold their China subsidiaries within the past year. Hanmi Pharmaceutical (Hanmi Pharm)'s Beijing Hanmi Pharmaceutical, a local subsidiary of Hanmi Pharm in China, is a
- Company
- Why SK Chemicals applied for EUA, not SK Biosicence
- by Kim, Jin-Gu Sep 11, 2024 05:54am
- SK Chemicals has applied for emergency use approval of the Novavax COVID-19 vaccine to the Ministry of Food and Drug Safety to introduce the vaccine to Korea. One interesting fact is that it was SK Chemicals, not SK Bioscience, that applied for the EUA. This is because the regulations for EUA require a prior record of vaccine imports. Sin
- Company
- The export performance of biopharma is up
- by Kim, Jin-Gu Sep 10, 2024 05:48am
- The export performance of two out of three pharmaceutical and biotech companies is reported to have increased year-over-year (YoY). The total export sales of 24 companies increased from KRW 3.6869 trillion to KRW 4.8975 trillion over the year, up 33%. In particular, the export performance of Samsung Biologics, Celltrion, and SK Biopharm
